Verastem’s Dual-Pronged Attack Shows New Promise Against Pancreatic Cancer

BOSTON, MA – June 17, 2026 – For decades, a diagnosis of metastatic pancreatic cancer has been a near-certain death sentence, a disease defined by its aggressive resistance to treatment and a grim five-year survival rate of just 3%. The standard-of-care has offered only incremental gains, leaving a vast unmet need for transformative therapies. Now, Boston-based Verastem Oncology has unveiled data that offers a significant glimmer of hope, showcasing a sophisticated strategy that goes beyond simply fighting the tumor to outsmarting its defenses.

In an announcement that has captured the attention of clinicians and investors, the biopharmaceutical firm reported positive updated results from its RAMP 205 Phase 1b/2a trial. The study evaluates a novel combination therapy in patients receiving their first treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). The early findings are compelling: at a median follow-up of 9.8 months, the combination demonstrated an 86% overall survival rate at six months, a 52% confirmed objective response rate (ORR), and tumor shrinkage in 83% of the 29 patients. While the data is still maturing, these figures stand out sharply against the historical benchmarks of standard chemotherapy, which typically yield response rates in the 20-30% range.

A Multi-Pronged Attack on a Notoriously Resistant Cancer

What makes Verastem’s approach strategically significant is its biological rationale. The company is not just adding another drug to the mix; it is executing a calculated, two-pronged assault on the core drivers of pancreatic cancer. More than 90% of these tumors are fueled by mutations in the KRAS gene, which activates the RAS/MAPK signaling pathway, effectively acting as the cancer's engine.

Verastem’s avutometinib is a novel RAF/MEK “clamp” designed to shut down this engine. However, history has shown that targeting this pathway alone often fails, as cancer cells cleverly activate an escape route. This alternate survival signal is frequently mediated by a protein called Focal Adhesion Kinase (FAK). This is where the second part of the combination, defactinib, comes in. As a potent FAK inhibitor, it blocks the escape route, trapping the cancer cell.

This dual-inhibition strategy—shutting down the main engine while simultaneously blocking the emergency exit—is designed to create a more complete and durable blockade of the signals driving tumor growth and drug resistance. The combination is then added to the standard chemotherapy backbone of gemcitabine and nab-paclitaxel, creating a powerful trifecta.

“The updated data from the RAMP 205 trial provide important clinical insights into the potential impact of combined RAF/MEK and FAK inhibition as a therapeutic option for pancreatic cancer,” said John Hayslip, M.D., chief medical officer at Verastem Oncology. He noted that the early survival trends and deep responses suggest the combination “may help overcome resistance mechanisms inherent in pancreatic cancer.”

Translating Early Data into Strategic Value

The 52% objective response rate reported in RAMP 205 is the kind of early signal that commands attention in oncology. For context, the standard chemotherapy regimen of gemcitabine plus nab-paclitaxel—used as the backbone in this very study—historically produces response rates of around 23%. The more aggressive FOLFIRINOX regimen pushes this into the 30-40% range, but with significantly higher toxicity. Verastem’s combination appears to be delivering a response rate that could represent a meaningful step-change for first-line therapy, provided the results hold up in larger trials.

The 6-month overall survival rate of 86% is another key metric. While overall survival data is still maturing, this early look is highly encouraging in a disease where median overall survival has hovered stubbornly between 8 and 11 months for years. The fact that nine of the 29 patients remained on treatment at the data cutoff further suggests a durable clinical benefit for a subset of patients.

From a strategic standpoint, these results do more than just offer hope to patients; they validate Verastem's core scientific thesis and de-risk its development pipeline. The combination of avutometinib and defactinib, co-packaged as AVMAPKI FAKZYNJA CO-PACK, has already secured an accelerated FDA approval for treating KRAS-mutated low-grade serous ovarian cancer. This prior regulatory success provides a crucial beachhead, demonstrating the combination's manageable safety profile and Verastem's ability to navigate the regulatory pathway.

The Power of Strategic Alliances and a Focused Pipeline

Verastem's journey with RAMP 205 is also a masterclass in strategic collaboration. The trial is supported by a $3.8 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), a highly respected advocacy and research organization. This partnership provides not only non-dilutive funding—a significant boon for a clinical-stage biotech—but also invaluable third-party validation from leading experts in the field.

“For patients and their families facing a pancreatic cancer diagnosis, every advance in research and understanding of the underlying biology driving this cancer matters,” said Anna Berkenblit, M.D., chief scientific and medical officer of PanCAN. The organization’s investment underscores the perceived potential of Verastem’s approach to make a real difference.

This success in pancreatic cancer fits neatly into Verastem's broader corporate strategy. The company has positioned itself as a leader in tackling RAS/MAPK pathway-driven cancers. Beyond the avutometinib/defactinib combination, its pipeline includes VS-7375, an oral inhibitor targeting the KRAS G12D mutation, which is the most common KRAS subtype in pancreatic cancer. This demonstrates a long-term vision to build a franchise of therapies that can be used in different combinations and lines of treatment for some of oncology's toughest challenges.

“We will continue to evaluate the potential role of avutometinib plus defactinib in metastatic pancreatic cancer, including future development opportunities and potential strategic collaborations, informed by the final overall survival results from the study,” stated Dan Paterson, president and chief executive officer of Verastem Oncology. This forward-looking statement signals that the company is already planning the next strategic moves, which could include a pivotal Phase 3 trial and partnerships to maximize the asset's value.

The road from a promising Phase 1/2 trial to a new standard of care is long and fraught with risk. The full overall survival data will be critical, and a larger, randomized confirmatory trial will be required for regulatory approval. However, for the first time in a long time, the strategy for fighting pancreatic cancer is evolving beyond brute-force chemotherapy. Verastem's calculated, science-driven approach shows that by understanding and targeting a cancer's fundamental survival mechanisms, it may be possible to change the narrative for one of the world's deadliest diseases.